UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

for the quarterly period ended June 30, 2023

 

OR

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the period from                to               .

 

Commission file number: 333-208814

 

SATIVUS TECH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   47-2847446

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

#3 Bethesda Metro Center, #700

Bethesda, Md 20814

  06880
(Address of principal executive offices)   (Zip Code)

 

800 608-6432

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 day. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐   No

 

(Does not currently apply to the Registrant)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 if the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No

 

As of August 10, 2023, the registrant had 4,215,571 shares of its Common Stock, $0.001 par value, outstanding.

 

When used in this quarterly report, the terms “Sativus Tech Corp.” “the Company,” “we,” “our,” and “us” refer to Sativus Tech Corp.

 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION 1
     
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS F-1
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 5
ITEM 4. CONTROLS AND PROCEDURES 5
     
PART II OTHER INFORMATION 6
     
ITEM 6. EXHIBITS 6
     
SIGNATURES 7

 

i

 

 

PART I. Financial Information

 

SATIVUS TECH CORP.

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
As of June 30, 2023

 

 

 

1

 

 

 

SATIVUS TECH CORP.

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2023

 

IN THOUSANDS OF U.S. DOLLARS

 

INDEX

 

  Page
Condensed Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022 F-2
   
Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited) F-3
   
Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the Six and Three Months Ended June 30, 2023 and 2022 (unaudited) F-4
   
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 (unaudited) F-5
   
Notes to Unaudited Consolidated Financial Statements F-6 – F-16

 

- - - - - - - - - - - -

 

F-1

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

 

   June 30,   December 31, 
   2023   2022 
   (Unaudited)     
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents  $642   $810 

Short-term deposits 

   801    6 
Other current assets   49    85 
Total current assets   1,492    901 
           
NON-CURRENT ASSETS          
Right-of-use asset   22    30 
Property and equipment, net   247    219 
Total non-current assets   269    249 
           
Total assets  $1,761   $1,150 
           
LIABILITIES AND SHAREHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
           
Accounts payables   36    55 
Loans   
-
    114 
Other current liabilities   120    160 
Convertible loans   1,995    2,031 
Fair value of convertible component in convertible loans   2,073    1,327 
Short term lease liability   27    32 
Total Liabilities   4,251    3,719 
           
SHAREHOLDER’S DEFICIT          
Ordinary shares of $0.0001 par value          
Authorized: 500,000,000 shares at June 30, 2023 and December 31, 2022; Issued and Outstanding: 4,215,571 and 4,215,571 shares at June 30, 2023 and December 31, 2022, respectively   4    4 
Additional Paid in capital   20,625    19,756 
Accumulated deficit   (23,786)   (22,604)
    (3,157)   (2,844)
Non-controlling interests   667    275 
Total shareholders’ deficit   (2,490)   (2,569)
           
Total liabilities and shareholders’ deficit  $1,761   $1,150 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-2

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)

U.S. dollars in thousands, except share and per share data

 

   Three months ended   Six months ended 
   June 30,
2023
   June 30,
2022
   June 30,
2023
   June 30,
2022
 
Operating expenses:                
Research and development  $93   $(211)  $(140)  $(276)
                     
Selling and marketing   
-
    
-
    
-
    
-
 
                     
General and administrative   (146)   (209)   (305)   (301)
                     
Operating loss   (53)   (420)   (445)   (577)
                     
Financial income (expenses), net   (947)   (260)   (871)   318 
                     
Net loss  $(1,000)   (680)  $(1,316)  $(259)
                     
Non-controlling interests   (4)   (68)   (134)   (95)
Net loss attributable to equity holders of the Company   (996)   (612)   (1,182)   (164)
                     
Basic and diluted net loss per share
  $(0.24)   (0.15)  $(0.28)  $(0.04)
                     
Weighted average number of Ordinary shares used in computing basic and diluted loss per share
   4,215,571    4,194,385    4,215,571    4,194,385 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-3

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

U.S. dollars in thousands, except share and per share data

 

   Ordinary shares   Additional
Paid in
   Accumulated   Total
Shareholders’
   Non-
controlling
     
   Number   Amount   capital   Deficit   Deficiency   interests   Total 
Balance as of January 1, 2022   4,194,385   $4   $18,595   $(21,077)  $(2,478)  $106   $(2,372)
Share based compensation to non-controlling parties   -    
-
    117    
-
    117    30    147 
Share Based Compensation to employees and non-employees   -    
-
    40    
-
    40    
-
    40 
Cancellation of share options in subsidiary   -    
-
    (168)   
-
    (168)   (43)   (211)
                                    
Net income (loss)   -    
-
    
-
    448    448    (27)   421 
Balance as of March 31, 2022 (Unaudited)   4,194,385   $4   $18,584   $(20,629)  $(2,041)  $66   $(1,975)
Share based compensation to non-controlling parties   -    
-
    101    
-
    101    26    127 
Share Based Compensation to employees and non-employees   -    
-
    35    
-
    35    
-
    35 
Net income (loss)   -    
-
    
-
    (612)   (612)   (68)   (680)
Balance as of June 30, 2022 (Unaudited)   4,194,385   $4   $18,720   $(21,241)  $(2,517)  $24   $(2,493)

 

   Ordinary shares   Additional
Paid in
   Accumulated   Total
Shareholders’
   Non-
controlling
     
   Number   Amount   capital   Deficit   Deficiency   interests   Total 
Balance as of January 1, 2023   4,215,571   $4   $19,756   $(22,604)  $(2,844)  $275   $(2,569)
Share based compensation to non-controlling parties   -    
-
    25    
-
    25    14    39 
Share Based Compensation to employees and non-employees   -    
-
    35    
-
    35    
-
    35 
Transactions with non-controlling parties   -    
-
    767    
-
    767    507    1,274 
                                    
Net income (loss)   -    
-
    
-
    (186)   (186)   (130)   (316)
Balance as of March 31, 2023 (Unaudited)   4,215,571   $4   $20,583   $(22,790)  $(2,203)  $666   $(1,537)
Share based compensation to non-controlling parties   -    
-
    15    
-
    15    11    26 
Share Based Compensation to employees and non-employees   -    
-
    35    
-
    35    
-
    35 
Cancellation of share options in subsidiary   -    
-
    (8)   
-
    (8)   (6)   (14)
Net loss   -    
-
    
-
    (996)   (996)   (4)   (1,000)
Balance as of June 30, 2023 (Unaudited)   4,215,571   $4   $20,625   $(23,786)  $(3,157)  $667   $(2,490)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-4

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

U.S. dollars in thousands

 

   Six months ended 
   June, 
   2023   2022 
Cash flows from operating activities:        
Net loss  $(1,316)  $(259)
Adjustments to reconcile loss to net cash used in operating activities:          
Depreciation and amortization   23    27 
Share based compensation expenses to employees and non-employees   121    110 
Financial expenses related to convertible loans and warrants   91    (1,290)
Change in fair value of convertible component in convertible loans   747    948 
           
Changes in assets and liabilities:          
Decrease in other accounts receivable   36    (30)
Increase in trade payables   (19)   34 
Decrease in other current liabilities   (40)   (34)
Net cash used in operating activities   (357)   (494)
           
Cash flows from investing activities:          
Decrease (Increase) in short-term deposits   (795)   9 
Purchase of property and equipment   (44)   (199)
Net cash used in investing activities   (839)   (190)
           
Cash flows from financing activities:          
Proceeds from convertible loans   
-
    50 
Lease payments   (10)   (15)
Repayment of convertible loans   (121)   (75)
Repayment of short term loans   (114)   
-
 
Proceeds from issuance of shares to minority interests in subsidiary   1,273    
-
 
Net cash provided (used) by financing activities   1,028    (40)
           
Increase (decrease) in cash and cash equivalents   (168)   (724)
Cash and cash equivalents at the beginning of the year   810    866 
Cash and cash equivalents at the end of the period  $642   $142 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $
-
   $75 
Conversion of convertible loans  $
-
   $
-
 
Purchase of fixed assets by issuance of share capital  $
-
   $28 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-5

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 1:- GENERAL

 

  a. SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligent algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 54% of Saffron Tech.

  

The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants and mushrooms. Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.

 

It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. Accounting to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for harmful pesticides and herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.

 

Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the textile industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.

 

  b. The Company has an accumulated deficit in the total amount of $23,786 as of June 30, 2023, the Company has negative operating cash flow in the total amount of $357 for the six months ended June 30, 2023, further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.

 

The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods.

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

 

The consolidated financial statements for the six months ended June 30, 2023, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

 

F-6

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation:

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”)

 

All intercompany accounts and transactions have been eliminated in consolidation.

 

Unaudited Interim Financial Information

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023 (the “2022 Annual Report”). The results for any interim period are not necessarily indicative of results for any future period.

 

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the three and six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.

 

As of June 30, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report.

 

F-7

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Fair value of financial instruments

 

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  Level 1 — Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
     
  Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
     
  Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying amounts of cash and cash equivalents, short term deposits, trade receivables, trade payables and short-term loan approximate their fair value due to the short-term maturity of such instruments.

 

The Company elected to measure some of the convertible loans under the fair value option. Under the fair value option the convertible loans will be measured at fair value in each reporting period until they will be converted, with changes in the fair values being recognized in the Company’s consolidated statement of operations as financial income or expense. The proceeds received for the issuance of the convertible loans were allocated at fair value conducted on an arm’s-length basis.

 

The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:

 

   Balance as of June 30, 2023 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $2,073   $2,073 
                     
Total liabilities  $
-
   $
-
   $2,073   $2,073 

 

   Balance as of December 31, 2022 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $1,327   $1,327 
                     
Total liabilities  $
-
   $
-
   $1,327   $1,327 

 

F-8

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 3:- CONVERTIBLE LOANS

 

  a. On February 21, 2019, the Company received a convertible loan from third party (“February 2019 Lender”), with a two-year term, in the principal amount of $550, which bears 10% annual interest rate (“February 2019 Loan”).

 

The Company at its option shall have the right to redeem, in part or in whole, outstanding principal amount and interest under this loan agreement prior to the maturity date. The Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding principal amount being redeemed plus outstanding and accrued interest.

 

The February 2019 Lender shall be entitled to convert at its option any portion of the outstanding and unpaid principal or accrued interest into fully paid and nonassessable of shares of common stock, at the lower of the fixed conversion price then in effect or the market conversion price. The number of shares of common stock issuable upon conversion of any conversion amount shall be determined by dividing (x) such conversion amount by (y) the fixed conversion price of $20.00 or (z) 80% of the lowest the volume-weighted average price of the Company’s shares of common stock during the 30 trading days immediately preceding the conversion date.

 

The Company accounted for the February 2019 Loan in accordance with ASC 470-20, Debt with conversion and other Options. As of December 31, 2022, the BCF was revalued at $326.

 

During the year ended December 31, 2020, a portion of the February 2019 Loan in the amount of $190 and accrued interest of $87 was converted into 1,045,521 Shares.

 

On February 20, 2021, the Company and the February 2019 Lender extended the February 2019 Loan to November 10, 2021.

 

On May 12, 2021, a portion of the February 2019 Loan in the amount of $60 and accrued interest of the February 2019 Loan in the amount of $14 was paid by the Company.

 

On January 26, 2022, the Company paid accrued interest of the February 2019 Loan in the amount of $20, and the February 2019 Loan agreement was extended until December 31, 2022. On December 10, 2022, the February 2019 Loan agreement was extended until June 30, 2023. As of June 30, 2023, the Company has defaulted on the February 2019 Loan. On July 31, the February 2019 Loan agreement was extended until December 30, 2023.

 

Conversion feature

 

In accordance with ASC 815-15-25 the conversion feature was considered an embedded derivative instrument, and is to be recorded at its fair value separately from the convertible notes, within current liabilities in the Company’s balance sheet. The conversion component is then marked to market at each reporting period with the resulting gains or losses shown in the statements of operations.

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $59 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.156 

 

The February 2019 Loan is included in the convertible loans in current liabilities as of June 30, 2023, in the amount of $347, and $332 as of December 31, 2022.

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to February 2019 Loan in the amount of $71, and financial income in the amount of $301 in the six months ended June 30, 2022.

 

F-9

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 3:- CONVERTIBLE LOANS (cont.)

 

  b. On October 15, 2019, the Company received a convertible loan from a third party (“October 2019 Lender”) in the principal amount of $1,100 that bears an annual 10% interest rate (“October 2019 Loan”). The October 2019 Loan has a two-year term. Prior to the maturity date of the October 2019 Loan, the Company, at its option, has the right to redeem, in cash, in part or in whole, the amounts outstanding provided that as of the date of the redemption notice (i) the volume-weighted average price of the Company’s ordinary shares is less than $12.50 and (ii) there is no equity condition failures as defined therein. In the event that the Company wishes to redeem any amount under the convertible loan, the Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding amount being redeemed in addition to outstanding and accrued interest.

 

The October 2019 Lender shall be entitled to convert the principal loan and the outstanding interest (the “Conversion Amount”) into such number of ordinary shares determined by dividing (x) such Conversion Amount by (y) the fixed conversion price of $12.50 or (z) 80% of the lowest the volume-weighted average price of the Company’s ordinary shares during the 10 trading days immediately preceding the conversion date.

 

The Company accounted for the October 2019 Loan in accordance with ASC 470-20, Debt with conversion and other Options. As of December 31, 2022, the BCF was revalued at $732.

 

As of December 31, 2021, the Company has defaulted on the October 2019 Loan and the October 2019 Loan was presented in fair value in financial statements for the year ended December 31, 2021.

 

On January 26, 2022, the Company paid accrued interest of the October 2019 Loan in the amount of $55, and the October 2019 Loan agreement was extended until December 31, 2022.

 

On December 20, 2022, the Company paid accrued interest of the October 2019 Loan in the amount of $100, and the October 2019 Loan agreement was extended until June 30, 2023. As of June 30, 2023, the Company has defaulted on the October 2019 Loan. On July 31, the October 2019 Loan agreement was extended until December 30, 2023.

  

Conversion feature

 

In accordance with ASC 815-15-25 the conversion feature was considered an embedded derivative instrument, and is to be recorded at its fair value separately from the convertible notes, within current liabilities in the Company’s balance sheet. The conversion component is then marked to market at each reporting period with the resulting gains or losses shown in the statements of operations.

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $210 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 

 

The October 2019 Loan is included in the convertible loans in current liabilities as of June 30, 2023, in the amount of $1,259, and $778 as of December 31, 2022.

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to October 2019 Loan in the amount of $678, and financial income in the amount of $1,101 in the six months ended June 30, 2022.

 

  c. On August 7, 2020, the Company received a convertible loan from a third party (“August 2020 Lender”) in the amount of $200 (the “August 2020 Loan”). Per the terms of the Agreement, the August 2020 Loans has a maturity date of August 7, 2022, (“Maturity Date”) and accrues annual interest at a rate of 10%

 

The August 2020 Loan is convertible by the August 2020 Lender into Shares, at their discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).

 

F-10

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 3:- CONVERTIBLE LOANS (cont.)

 

The Company also granted the August 2020 Investor warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $2.00 per share, such exercise price is subject to any future price-based anti-dilution adjustments. Accordance with ASU 2017-11 the warrants were classified in shareholders equity.

 

The fair value of the warrants granted was $35 using the Black-Scholes-Merton option pricing model using the following assumptions:

 

   August
2020
 
Share price  $0.86 
Dividend yield   0%
Risk-free interest rate   0.21%
Expected term (in years)   5 
Volatility   176.96%

 

The Company accounted for the August 2020 Loan in accordance with ASC 470-20, Debt with conversion and other Options. The combined intrinsic value of the BCF for the August 2020 Loan was calculated and valued at $249 as of August 7, 2020, and the Company allocated $249 to the BCF as a liability. As of December 31, 2021, the BCF was revalued at $146 ($339 as of December 31, 2020).

 

As of June 30, 2023, the Company has defaulted on the August 2020 Loan. On July 31, the August 2020 Loan agreement was extended until December 30, 2023.

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $43 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 

 

The August 2020 Loan is included in the convertible loans in short term liabilities as of June 30, 2023 in the amount of $259, and $249 as of December 31, 2022.

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to August 2020 Loan in the amount of $130, and interest and financial expenses in the amount of $44 in the six months ended June 30, 2022.

 

  d. From November 2020 through to December 31, 2020, the Company received $425 from third party investors from the issuance of convertible promissory notes (“2020 Promissory Notes”). The Promissory Notes bear no interest, are convertible into Shares based on a fixed conversion price of $1.00 per share and mature between 6 and 24 months from the issuance date. Pursuant to the 2020 Promissory Notes, one of the investors received warrants to purchase 33,000 Shares at an exercise price of $1.50 through to December 17, 2021. (“2020 Promissory Warrants”)

 

From January 2021 through to February 16, 2021, the Company received an additional $530 from third party investors from the issuance of Promissory Notes (“2021 Promissory Notes). One of the investors received 33,000 warrants (“2021 Promissory Warrants”). The 2021 Promissory Warrants have the same terms as the 2020 Promissory Notes. During December 2021 the 2020 Promissory Warrants and the 2021 Promissory Warrants were extended to December 31, 2022.

 

During the year ended December 31, 2021, Promissory Notes in the amount of $830 have been converted into shares. On December 14, 2022, Promissory Notes in the amount of $100 were repaid to the investors.

 

F-11

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 3:- CONVERTIBLE LOANS (cont.)

 

  e. On July 31, 2020, the Company received a convertible loan from Mr. Shmuel Yannay (a third party at that time, and a director of the Company as of October 28, 2021) in the amount of $100 (“Director Loan”). The loan has a maturity date of July 31, 2022 (“Maturity Date”) and accrues annual interest at a rate of 10%

 

The Director Loan is convertible into Shares, at his discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).

 

The Company also granted the Mr. Yannay warrants to purchase 25,000 shares of common stock of the Company at an exercise price of $2.00 per share, such exercise price is subject to any future price-based anti-dilution adjustments. Accordance with ASU 2017-11 the warrants were classified in shareholders equity.

 

The fair value of the warrants granted was $18 using the Black-Scholes-Merton option pricing model using the following assumptions:

 

   August
2020
 
Share price  $0.86 
Dividend yield   0%
Risk-free interest rate   0.21%
Expected term (in years)   5 
Volatility   176.96%

 

The Company accounted for the director’s loan in accordance with ASC 470-20, Debt with conversion and other Options. The combined intrinsic value of the BCF for the August 2020 Loan was calculated and valued at $129 as of July 31, 2020, and the Company allocated $129 to the BCF as a liability. As of June 30, 2023, the BCF was revalued at $18 ($88 as of December 31, 2022).

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $18 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to Director Loan in the amount of $53, and interest and financial expenses in the amount of $18 in the six months ended June 30, 2022.

 

F-12

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 4:- RELATED PARTIES

 

The following transactions arose with related parties:

 

   Six months ended June 30, 2023   Amounts
 owing
 
   Directors
Fees
   Consulting
Fees /
Salaries
   Interest   Total   by (to) as of
June 30,
2023
 
Director and CEO  $
       -
   $82   $
-
   $82   $(13)
CFO   
-
    36    
-
    36    (5)
Company controlled by CFO   
-
    26    
-
    26    
-
 
Directors   
-
    42    26    68    (112)
   $
-
   $186   $26   $212   $(130)

 

   Six months ended June 30, 2022   Amounts
 owing
 
   Directors
Fees
   Consulting
Fees /
Salaries
   Interest   Total   by (to) as of
June 30,
2022
 
Director and CEO  $
       -
   $59   $         $59   $
      -
 
CFO   
-
    36         36    (18)
Company controlled by CFO   
-
    26    
-
    26    
-
 
Directors   
-
    
-
    5    5    (115)
   $
-
   $121   $5   $126   $(133)

 

NOTE 5:- SHAREHOLDERS’ DEFICIT

 

  a. As of June 30, 2023 and December 31, 2022, the Company’s share capital is composed as follows:

 

   June 30,
2023
   December 31,
2022
 
   Authorized   Issued and
outstanding
   Issued and
outstanding
   Issued and
outstanding
 
   Number of shares 
Shares of common stock of $0.0001 par value each “Shares”   500,000,000    4,215,571    500,000,000    4,215,571 

 

  b. Warrants

 

A summary of warrant activity during the six months period ended June 30, 2023, and year ended December 31, 2022 is as follows:

 

   Number   Average
exercise
price
 
Warrants outstanding at January 1, 2022   198,750   $5.40 
Granted   
-
    
-
 
Exercised   
-
    
-
 
Forfeited/Cancelled   (13,750)   2.00 
Forfeited/Cancelled   (66,000)   1.50 
Warrants outstanding at December 31, 2022   119,000   $5.88 
Expired   
-
    
-
 
Exercised   
-
    
-
 
Forfeited/Cancelled   
-
    
-
 
Warrants outstanding at June 30, 2023   119,000   $5.88 

 

F-13

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 5:- SHAREHOLDERS’ DEFICIT (cont.)

 

The following warrants are outstanding as of December 31, 2022:

 

Issuance date  Warrants
outstanding
   Exercise
price per
warrant
   Warrants
outstanding and
exercisable
   Expiry date
October 15, 2019   44,000   $12.50    44,000   October 15, 2024
August 7, 2020   50,000   $2.00    50,000   August 7, 2025
August 11, 2020   25,000   $2.00    25,000   August 11, 2025
    119,000         119,000    

 

The following warrants and are outstanding as of June 30, 2023:

 

Issuance date  Warrants
outstanding
   Exercise
price per
warrant
   Warrants
outstanding and
exercisable
   Expiry date
October 15, 2019   44,000   $12.50    44,000   October 15, 2024
August 7, 2020   50,000   $2.00    50,000   August 7, 2025
August 11, 2020   25,000   $2.00    25,000   August 11, 2025
    119,000         119,000    

 

  c. Share option plans:

 

On April 1, 2019, the Company’s board of directors adopted the Sativus Tech Corp. 2018 Share Options Plan (the “2018 Plan”).

 

Awards granted under the 2018 Plan are subject to vesting schedules and unless determined otherwise by the administrator of the 2018 Plan, generally vest following a period of four years from the applicable vesting commencement date, such that the awards vest in four annual equal instalments and/or generally vest following a period of one year from the applicable vesting commencement date, such that the awards vest in four quarterly equal instalments.

  

(i)A summary of employee share options activity during the six-month period ended June 30, 2023, and for the year ended December 31, 2022, is as follows:

 

   Number   Average
weighted
exercise
price
 
Options outstanding at January 1, 2022   195,000   $0.63 
Granted   45,000    1.00 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Options outstanding at December 31, 2022   240,000   $0.70 
Granted   
-
    
-
 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Options outstanding at June 30, 2023   240,000   $0.70 
           
Options exercisable at June 30, 2023   223,750   $0.72 

 

F-14

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 5:- SHAREHOLDERS’ DEFICIT (cont.)

 

The following options are outstanding as of June 30, 2022:

 

Issuance date  Options
outstanding
   Exercise
price per
option
   Options
outstanding and
exercisable
   Expiry date
September 1, 2020   15,000   $0.70    13,750   September 1, 2025
October 13, 2020   50,000   $1.00    50,000   October 12, 2023
November 3, 2020   25,000   $1.00    25,000   October 25, 2025
November 3, 2020   25,000   $1.50    25,000   October 25, 2025
December 14, 2021   80,000   $0.01    72,500   December 14, 2026
November 15, 2022   45,000   $1.00    37,500   November 15, 2024
    240,000         223,750    

 

  d. Restricted Share Units:

 

RSUs under the 2018 Plan may be granted upon such terms and conditions, no monetary payment (other than payments made for applicable taxes) shall be required as a condition of receiving the Company’s shares pursuant to a grant of RSUs, and unless determined otherwise by the Company, the aggregate nominal value of such RSUs shall not be paid and the Company shall capitalize applicable profits or take any other action to ensure that it meets any requirement of applicable laws regarding issuance of shares for consideration that is lower than the nominal value of such shares. If, however, the Company’s board of directors determines that the nominal value of the shares shall not be waived and shall be paid by the grantees, then it shall determine procedures for payment of such nominal value by the grantees or for collection of such amount from the grantees by the Company.

 

Shares issued pursuant to any RSUs units may (but need not) be made subject to exercise conditions, as shall be established by the Company and set forth in the applicable notice of grant evidencing such award. During any restriction period in which shares acquired pursuant to an award of RSUs remain subject to exercise conditions, such shares may not be sold, exchanged, transferred, pledged, assigned or otherwise disposed of unless otherwise provided in the 2018 Plan. Upon request by the Company, each grantee shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares hereunder and the Company may place appropriate legends evidencing any such transfer restrictions on the relevant share certificates.

 

A summary of RSU activity during the six months ended June 30, 2023, and the year ended December 31, 2022 is as follows:

 

    Number  
RSU outstanding at January 1, 2022     196,000  
Granted     370,000  
Exercised     -  
Forfeited     (30,000 )
RSU outstanding at December 31, 2022     536,000  
Granted     -  
Exercised     -  
Forfeited     (5,000
RSU’s outstanding at June 30, 2022     531,000  

 

F-15

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

NOTE 6:- FINANCIAL INCOME (EXPENSES)

 

   Three months ended   Six months ended 
   June 30,
2023
   June 30,
2022
   June 30,
2023
   June 30,
2022
 
                 
Financial income (expenses) related to interest and revaluation of convertible component in convertible loans  $(911  $(250)  $(832  $346 
                     
Financial expenses related to warrants   
-
    
-
    
-
    
-
 
                     
Foreign currency transactions and other   (36)   (10)   (39)   (28)
                     
    (947   (260)   (871   318 

 

NOTE 7:- LIENS, COMMITMENTS

 

Saffron leases its facility on a lease that expires on September 11, 2024. Lease payments are approximately $2 per month ($23 annually).  

 

Saffron Tech is committed to pay royalties to the IIA on the proceeds from sales of products resulting from research and development projects in which the IIA participates by way of grants. In the first 3 years of sales the Company shall pay 3% of the sales of the product which was developed under IIA research and development projects. In the fourth, fifth and sixth years of sales, the Company shall pay 4% of such sales and from the seventh year onwards the Company shall pay 5% of up to 100% of the amount of grants received plus interest at LIBOR. Saffron Tech was entitled to the grants only upon incurring research and development expenditures. There were no future performance obligations related to the grants received from the IIA. As of June 30, 2023, the contingent liabilities with respect to grants received from the IIA, subject to repayment under these royalty agreements on future sales is $Nil. As of June 30, 2023, Saffron Tech received a total of $395 from the IIA

 

  NOTE 8:- SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report. 

 

F-16

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH OUR AUDITED FINANCIAL STATEMENTS AND THE RELATED NOTES THAT APPEAR ELSEWHERE IN THIS QUARTERLY REPORT ON FORM 10-Q AND THE FINANCIAL STATEMENTS AND RELATED NOTES THERETO FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 AND THE RELATED MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, BOTH OF WHICH ARE CONTAINED IN OUR ANNUAL REPORT ON FORM 10-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), ON MARCH 31, 2023. PAST OPERATING RESULTS ARE NOT NECESSARILY INDICATIVE OF RESULTS THAT MAY OCCUR IN FUTURE PERIODS. THE FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT REFLECT OUR PLANS, ESTIMATES AND BELIEFS. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE THOSE DISCUSSED BELOW AND ELSEWHERE IN THIS QUARTERLY REPORT.

 

FORWARD-LOOKING STATEMENTS

 

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties. Although we believe that the expectations reflected-in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our actual results may differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this report, and we assume no obligation to update these forward-looking statements whether as a result of new information, future events, or otherwise, other than as required by law. In light of these assumptions, risks, and uncertainties, the forward-looking events discussed in this report might not occur and actual results and events may vary significantly from those discussed in the forward-looking statements. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended March 31, 2022. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

 

When used in this quarterly report, the terms “Sativus,” “the Company,” “we,” “our,” and “us” refer to SATIVUS TECH CORP., a Delaware corporation, unless otherwise indicated or as otherwise required by the context.

 

Company Overview

 

SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligent algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 54% of Saffron Tech.

 

The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants and mushrooms. Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.

 

It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. Accounting to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for harmful pesticides and herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.

 

Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the textile industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.

 

2

 

 

On January 6, 2022, the Company announced that its subsidiary, Saffron Tech, has planted approximately 25,000 Saffron bulbs in fields in the Golan Heights, in Norther Israel. The plantation is being managed in conjunction with the Shamir Research Institute.

 

On April 4, 2022, the Company announced that Mr. Moshe Bar Siman Tov and Mrs. Iris Tova Ginsburg have resigned from the Board of Directors of the Company, and immediately appointed Mrs. Tal Wilk-Glazer to its Board of Directors and as CEO of the Company.

 

In April 2022, Saffron Tech announced its new state-of-the-art indoor research and development center is operational. From April 2022, through to December 2022, Saffron Tech successfully completed three Saffron cultivation cycles using vertical farming technology, while traditional agriculture only produces one harvest of saffron per year.

 

On August 30, 2022, Saffron Tech, announced its intention to raise up to 5 million New Israeli Shekels (“NIS”) (approximately $1.5 million) at a pre-money valuation of NIS 32.5 million (approximately $10 million) through the Israeli crowdfunding platform – Pipelbiz (“2022 Crowd Funding Round”). Assuming the maximum amount is raised, the Company will own approximately 61% of Saffron Tech. The 2022 Crowd Funding Round was closed on December 1, 2022, having raised 3.8 million NIS (approximately $1.3 million). Fundraising expenses accumulated to $152 and the net amount raised through Pipelbiz was $1.15 million. Saffron Tech also raised 1.15 million NIS (approximately $328 thousand) through the issuance of SAFEs. The SAFEs are convertible at a 20% discount to the current crowdfunding round. Sativus Tech’s interest in Saffron Tech now totals 67.5% post-raise. All SAFEs were converted before December 31, 2022. Saffron Tech continued to raise funds through Pipelbiz under the same pre-money valuation from December 2022 through to January 2023, via another crowdfunding round “2023 Crowd Funding Round” which closed on February 5, 2023, having raised another 1.1 million NIS (approximately $314 thousand).

 

On March 1, 2023, Saffron Tech entered into an investment agreement with Korean-based company, Dreamtech Co Ltd (“Dreamtech”), a leading provider and manufacturer of tech components for innovative products including advanced mobile and medical devices. Under this new agreement, Dreamtech will fund an initial investment of $1 million followed by an additional $1 million upon a successful cultivation of saffron in Korea. Saffron Tech aims to be the first company to create a large-scale production of saffron using vertical farming technology to meet the growing demand of the spice for use in beauty, wellness, and pharmaceutical applications. Sativus Tech’s interest in Saffron Tech now totals 59% post-raise.

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited condensed financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited condensed financial statements should be read in conjunction with our December 31, 2022, annual financial statements included in our Form 10-K, filed with the SEC on March 31, 2023.

 

Going Concern

 

Due to the uncertainty of our ability to meet our current operating and capital expenses, our independent auditors included an explanatory paragraph in their report on the condensed consolidated financial statements for the six months ended June 30, 2023, regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

 

Our unaudited condensed financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited condensed financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

 

3

 

 

Financing

 

We will require additional financing to implement our business plan, which may include joint venture projects and debt or equity financings. The nature of this enterprise and constraint of positive cash flow places debt financing beyond the credit-worthiness required by most banks or typical investors of corporate debt until such time as an economically viable profits and losses can be demonstrated. Therefore, any debt financing of our activities may be costly and result in substantial dilution to our stockholders.

 

Future financing through equity investments is likely to be dilutive to existing stockholders. Also, the terms of securities we may issue in future capital transactions may be more favorable for our new investors. Newly issued securities may include preferences, superior voting rights, and the issuance of warrants or other derivative securities, which may have additional dilutive effects. Further, we may incur substantial costs in pursuing future capital and financing, including investment banking fees, legal fees, accounting fees, and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such as convertible notes and warrants, which will adversely impact our financial condition.

 

Our ability to obtain needed financing may be impaired by such factors as the capital markets, both generally and specifically in the Agro-tech industry, which could impact the availability or cost of future financings. If the amount of capital we are able to raise from financing activities, together with our revenue from operations, is not sufficient to satisfy our capital needs, even to the extent that we reduce our operations accordingly, we may be required to cease operations.

 

There is no assurance that we will be able to obtain financing on terms satisfactory to us, or at all. We do not have any arrangements in place for any future financing. If we are unable to secure additional funding, we may cease or suspend operations. We have no plans, arrangements or contingencies in place in the event that we cease operations.

 

Results of Operations

 

Six months ended June 30, 2023 compared to the six months ended June 30, 2022

 

Operating Expenses

 

Research and development expenses for the six months ended June 30, 2023, were $140 thousand compared to $276 thousand for the same period in 2022. Gross research and development expenses were $535 thousand, offset by the amounts received in respect of participation in expenses by the Israeli Innovation Authority in the amount of $395 thousand (previous period – $117) which reduced total research and development expenses for the six months ended June 30, 2023, to $140 thousand.

  

General and administrative (“G&A”) expenses for the six months ended June 30, 2023, were $305 thousand compared to $301 thousand for the same period in 2022.

 

Total financial expenses for the six months ended June 30, 2023, were $871 compared to financial income in the amount of $318 thousand for the same period in 2022. Financial expenses and income are due mainly to financial gains or losses related to revaluations of convertible component in convertible loans.

 

Three months ended June 30, 2023 compared to the three months ended June 30, 2022

 

Operating Expenses

 

Research and development income for the three months ended June 30, 2023, was $93 thousand compared to expenses in the amount of $211 thousand for the same period in 2022. Gross research and development expenses in 2023 were $302 thousand, offset by the amounts received in respect of participation in expenses by the Israeli Innovation Authority in the amount of $395 which reduced total research and development expenses for the three months ended June 30, 2022, to income in the amount of $93 thousand.

  

General and administrative (“G&A”) expenses for the three months ended June 30, 2023, were $146 thousand compared to $209 thousand for the same period in 2022.

 

Total financial expenses for the three months ended June 30, 2023, were $947 compared to $260 thousand for the same period in 2022. Financial expenses are due mainly to financial losses related to revaluations of convertible component in convertible loans.

 

Liquidity and Capital Resources

 

Overview

 

Since inception on January 16, 2015, the Company has a cumulative deficit of $22,786 thousand and a working capital deficit of $2,759 thousand as of June 30, 2023. Our future growth is dependent upon achieving further purchase orders and execution, management of operating expenses and the ability of the Company to obtain the necessary financing to fund future obligations, and upon profitable operations.

 

Historically, we have financed our cash flow and operations from the initial contribution of our majority shareholder and by raising equity and convertible loans.

 

4

 

 

As of June 30, 2023, we had current assets of $1,492 thousand consisting of $642 thousand in cash and cash equivalents, $801 thousand in short-term deposits and $49 thousand in other current assets.

 

We had $4,251 thousand in current liabilities consisting of $120 thousand in other current liabilities, $1,995 thousand in Convertible loans, $2,073 thousand in convertible component, $27 thousand in short-term lease liability and $36 thousand accounts payables.

 

As of December 31, 2022, we had current assets of $901 thousand consisting of $810 thousand in cash and cash equivalents, $6 thousand in short-term deposits and $85 thousand in prepaid expenses and other receivables. We had $3,719 thousand in current liabilities, which consisted of $55 thousand in accounts payable, $114 thousand loans, $160 thousand other accounts payable, $2,031 thousand Convertible loans, $1,327 thousand in BCF liability, and $32 thousand in short term lease liability.

 

We had a negative working capital of $2,759 thousand and $2,818 thousand as of June 30, 2023, and December 31, 2022, respectively.

 

Our Current liabilities as of June 30, 2023, were $4,251 thousand compared to $3,719 thousand as of December 31, 2022.

 

During the six months ended June 30, 2023, we had negative cash flow from operations of $357 thousand which was mainly the result of a net loss of $1,316 thousand, offset by financial losses from revaluations of convertible component in convertible loans in the amount of $747 thousand.

 

During the six months ended June 30, 2023, we had negative cash flow from investing activities of $839 thousand compared to a negative cash flow from investing activities of $190 thousand during the six months ended June 30, 2022. The increase was mainly due to the increase in short term deposits in the amount of $795 thousand.

 

During the six months ended June 30, 2023, we had a positive cash flow from financing activities of $1,028 thousand compared to a negative cash flow from financing activities during the six months ended June 30, 2022. Cash flow from financing activities in the six months ended June 30, 2023, was a result of issuance of shares to minority interests in a subsidiary in the amount of $1,273 thousand, offset by repayment of loans and convertible loans in the amount of $235 thousand.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

In connection with the preparation of our Quarterly Report on Form 10-Q, an evaluation was carried out by management, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of June 30, 2023. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

During evaluation of disclosure controls and procedures as of June 30, 2023, conducted as part of our preparation of the quarterly unaudited condensed financial statements, management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures and concluded that our disclosure controls and procedures were not effective.

 

Changes in Internal Control Over Financial Reporting

 

As of the end of the period covered by this report, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

5

 

 

Part II- Other Information

 

Item 6. Exhibits

 

Exhibit
Number
  Description
10.1   Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
31.1*   Rule 13a-14(a) Certification of the Chief Executive Officer
31.2*   Rule 13a-14(a) Certification of the Chief Financial Officer
32.1**   Section 1350 Certification of Chief Executive Officer
32.2**   Section 1350 Certification of Chief Financial Officer
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

* Furnished herewith.

 

6

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated.

 

  SATIVUS TECH CORP.
     
Dated: August 10, 2023 By: /s/ Tal Wilk-Glazer
    Tal Wilk-Glazer
    Chief Executive Officer

 

 

7

 
MD 0.04 0.15 0.24 0.28 4194385 4194385 4215571 4215571 false --12-31 Q2 0001661600 0001661600 2023-01-01 2023-06-30 0001661600 2023-08-10 0001661600 2023-06-30 0001661600 2022-12-31 0001661600 2023-03-31 0001661600 2023-04-01 2023-06-30 0001661600 2022-04-01 2022-06-30 0001661600 2022-01-01 2022-06-30 0001661600 us-gaap:CommonStockMember 2021-12-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001661600 us-gaap:RetainedEarningsMember 2021-12-31 0001661600 us-gaap:ParentMember 2021-12-31 0001661600 us-gaap:NoncontrollingInterestMember 2021-12-31 0001661600 2021-12-31 0001661600 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001661600 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001661600 us-gaap:ParentMember 2022-01-01 2022-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001661600 2022-01-01 2022-03-31 0001661600 us-gaap:CommonStockMember 2022-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001661600 us-gaap:RetainedEarningsMember 2022-03-31 0001661600 us-gaap:ParentMember 2022-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2022-03-31 0001661600 2022-03-31 0001661600 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001661600 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001661600 us-gaap:ParentMember 2022-04-01 2022-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001661600 us-gaap:CommonStockMember 2022-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001661600 us-gaap:RetainedEarningsMember 2022-06-30 0001661600 us-gaap:ParentMember 2022-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2022-06-30 0001661600 2022-06-30 0001661600 us-gaap:CommonStockMember 2022-12-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001661600 us-gaap:RetainedEarningsMember 2022-12-31 0001661600 us-gaap:ParentMember 2022-12-31 0001661600 us-gaap:NoncontrollingInterestMember 2022-12-31 0001661600 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001661600 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001661600 us-gaap:ParentMember 2023-01-01 2023-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001661600 2023-01-01 2023-03-31 0001661600 us-gaap:CommonStockMember 2023-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001661600 us-gaap:RetainedEarningsMember 2023-03-31 0001661600 us-gaap:ParentMember 2023-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2023-03-31 0001661600 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001661600 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001661600 us-gaap:ParentMember 2023-04-01 2023-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001661600 us-gaap:CommonStockMember 2023-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001661600 us-gaap:RetainedEarningsMember 2023-06-30 0001661600 us-gaap:ParentMember 2023-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2023-06-30 0001661600 satt:SaffronTechsMember 2020-11-05 0001661600 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001661600 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001661600 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001661600 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001661600 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001661600 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001661600 2019-02-21 0001661600 satt:FebruaryTwoThousandNineteenLenderMember 2019-02-02 2019-02-21 0001661600 satt:FebruaryTwoThousandNineteenLenderMember 2019-02-21 0001661600 2022-01-01 2022-12-31 0001661600 satt:February2019LoanMember 2020-12-31 0001661600 satt:February2019LoanMember 2020-01-01 2020-12-31 0001661600 2021-05-01 2021-05-12 0001661600 2022-01-26 2022-01-26 0001661600 satt:February2019LoanMember 2023-01-01 2023-06-30 0001661600 satt:February2019LoanMember 2022-01-01 2022-12-31 0001661600 satt:February2019LoanMember 2023-06-30 0001661600 satt:February2019LoanMember 2022-06-30 0001661600 us-gaap:ConvertibleDebtMember 2019-10-15 2019-10-15 0001661600 satt:OctoberTwoThousandNineteenLenderMember 2023-06-30 0001661600 satt:OctoberTwoThousandNineteenLoanMember 2022-01-01 2022-12-31 0001661600 satt:OctoberTwoThousandNineteenLoanMember 2022-01-26 2022-01-26 0001661600 satt:OctoberTwoThousandNineteenLoanMember 2022-12-20 2022-12-20 0001661600 satt:OctoberTwoThousandNineteenLoanMember 2023-01-01 2023-06-30 0001661600 satt:OctoberTwoThousandNineteenLoanMember 2023-06-30 0001661600 satt:OctoberTwoThousandNineteenLoanMember 2022-06-30 0001661600 satt:August2020LoanMember 2020-08-07 0001661600 satt:August2020LoanMember 2020-08-01 2020-08-07 0001661600 satt:August2020LoanMember 2023-01-01 2023-06-30 0001661600 satt:August2020LoanMember 2021-01-01 2021-12-31 0001661600 satt:August2020LoanMember 2020-01-01 2020-12-31 0001661600 satt:August2020LoanMember 2023-06-30 0001661600 satt:August2020LoanMember 2022-12-31 0001661600 satt:AugustTwoThousandTwentyLendersMember 2023-06-30 0001661600 satt:August2020LoanMember 2022-06-30 0001661600 satt:TwentyTwentyPromissoryNotesMember 2020-12-31 0001661600 srt:MinimumMember 2023-01-01 2023-06-30 0001661600 srt:MaximumMember 2023-01-01 2023-06-30 0001661600 satt:TwentyTwentyPromissoryNotesMember 2021-12-17 2021-12-17 0001661600 satt:TwentyTwentyPromissoryNotesMember 2021-12-17 0001661600 satt:TwentyTwentyOneMember 2021-02-16 0001661600 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001661600 us-gaap:ConvertibleNotesPayableMember 2022-12-14 2022-12-14 0001661600 2020-07-31 2020-07-31 0001661600 satt:FixedConversionPriceMember 2023-06-30 0001661600 satt:VWAPMember 2023-06-30 0001661600 satt:MrYannayMember 2023-01-01 2023-06-30 0001661600 satt:MrYannayMember 2023-06-30 0001661600 satt:BCFMember 2020-07-31 2020-07-31 0001661600 srt:MinimumMember satt:MonteCarloSimulationModelMember 2023-06-30 0001661600 srt:MinimumMember satt:MonteCarloSimulationModelMember 2023-01-01 2023-06-30 0001661600 srt:MaximumMember satt:MonteCarloSimulationModelMember 2023-06-30 0001661600 srt:MaximumMember satt:MonteCarloSimulationModelMember 2023-01-01 2023-06-30 0001661600 satt:BlackScholesMertonOptionMember 2020-08-20 0001661600 satt:BlackScholesMertonOptionMember 2020-08-01 2020-08-20 0001661600 satt:BlackScholesMertonOptionMember 2023-06-30 0001661600 satt:BlackScholesMertonOptionMember 2023-01-01 2023-06-30 0001661600 satt:MonteCarloOptionMember 2020-08-20 0001661600 satt:MonteCarloOptionMember 2020-08-01 2020-08-20 0001661600 satt:MonteCarloOptionMember 2023-06-30 0001661600 satt:MonteCarloOptionMember 2023-01-01 2023-06-30 0001661600 srt:BoardOfDirectorsChairmanMember 2023-01-01 2023-06-30 0001661600 srt:BoardOfDirectorsChairmanMember 2023-06-30 0001661600 srt:ChiefFinancialOfficerMember 2023-01-01 2023-06-30 0001661600 srt:ChiefFinancialOfficerMember 2023-06-30 0001661600 satt:CompanyControlledByCFOMember 2023-01-01 2023-06-30 0001661600 satt:CompanyControlledByCFOMember 2023-06-30 0001661600 srt:DirectorMember 2023-01-01 2023-06-30 0001661600 srt:DirectorMember 2023-06-30 0001661600 srt:BoardOfDirectorsChairmanMember 2022-01-01 2022-06-30 0001661600 srt:BoardOfDirectorsChairmanMember 2022-06-30 0001661600 srt:ChiefFinancialOfficerMember 2022-01-01 2022-06-30 0001661600 srt:ChiefFinancialOfficerMember 2022-06-30 0001661600 satt:CompanyControlledByCFOMember 2022-01-01 2022-06-30 0001661600 satt:CompanyControlledByCFOMember 2022-06-30 0001661600 srt:DirectorMember 2022-01-01 2022-06-30 0001661600 srt:DirectorMember 2022-06-30 0001661600 satt:TwoZeroOneEightShareOptionsPlanMember 2023-01-01 2023-06-30 0001661600 satt:IssuanceDate8Member 2022-12-31 0001661600 satt:IssuanceDate8Member 2022-01-01 2022-12-31 0001661600 satt:AugustSevenTwoThousandTwentyMember 2022-12-31 0001661600 satt:AugustSevenTwoThousandTwentyMember 2022-01-01 2022-12-31 0001661600 satt:AugustElevenTwoThousandTwentyMember 2022-12-31 0001661600 satt:AugustElevenTwoThousandTwentyMember 2022-01-01 2022-12-31 0001661600 satt:IssuanceDate8Member 2023-06-30 0001661600 satt:IssuanceDate8Member 2023-01-01 2023-06-30 0001661600 satt:AugustSevenTwoThousandTwentyMember 2023-06-30 0001661600 satt:AugustSevenTwoThousandTwentyMember 2023-01-01 2023-06-30 0001661600 satt:AugustElevenTwoThousandTwentyMember 2023-06-30 0001661600 satt:AugustElevenTwoThousandTwentyMember 2023-01-01 2023-06-30 0001661600 satt:September12020Member 2022-01-01 2022-06-30 0001661600 satt:October132020Member 2022-01-01 2022-06-30 0001661600 satt:November32020Member 2022-01-01 2022-06-30 0001661600 satt:November32020OneMember 2022-01-01 2022-06-30 0001661600 satt:December142021Member 2022-01-01 2022-06-30 0001661600 satt:November152022Member 2022-01-01 2022-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Tal Wilke-Glazer, certify that:

 

1. I have reviewed this Form 10-Q of SATIVUS TECH CORP.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 10th, 2023 By: /s/ Tal Wilke-Glazer
    Tal Wilke-Glazer
   

Director, Chief Executive Officer

SATIVUS TECH CORP.

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Gadi Levin, certify that:

 

1. I have reviewed this Form 10-Q of SATIVUS TECH CORP.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 10th, 2023 By: /s/ Gadi Levin
    Gadi Levin
   

Chief Financial Officer

SATIVUS TECH CORP.

 

Exhibit 32.1

 

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of SATIVUS TECH CORP. (the “Company”) on Form 10-Q for the quarter ending June 30th, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Tal Wilke-Glazer, Director and Chief Executive Officer (Principal Executive Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.

Such Quarterly Report on Form 10-Q for the quarter ending June 30th, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in such Quarterly Report on Form 10-Q for the quarter ending June 30th, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 10th, 2023 By: /s/ Tal Wilke-Glazer
    Tal Wilke-Glazer
   

Director, Chief Executive Officer

SATIVUS TECH CORP.

 

Exhibit 32.2

 

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of SATIVUS TECH CORP. (the “Company”) on Form 10-Q for the quarter ending June 30th, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Gadi Levin, Chief Financial Officer (Principal Financial Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.

Such Quarterly Report on Form 10-Q for the quarter ending June 30th, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in such Quarterly Report on Form 10-Q for the quarter ending June 30th, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 10th, 2023 By: /s/ Gadi Levin
    Gadi Levin
   

Chief Financial Officer

SATIVUS TECH CORP.

 

v3.23.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 10, 2023
Document Information Line Items    
Entity Registrant Name SATIVUS TECH CORP.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   4,215,571
Amendment Flag false  
Entity Central Index Key 0001661600  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 333-208814  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-2847446  
Entity Address, Address Line One #3 Bethesda Metro Center  
Entity Address, Address Line Two #700  
Entity Address, City or Town Bethesda  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 06880  
City Area Code 800  
Local Phone Number 608-6432  
Entity Interactive Data Current No  
v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:    
Cash and cash equivalents $ 642 $ 810
Short-term deposits 801 6
Other current assets 49 85
Total current assets 1,492 901
NON-CURRENT ASSETS    
Right-of-use asset 22 30
Property and equipment, net 247 219
Total non-current assets 269 249
Total assets 1,761 1,150
CURRENT LIABILITIES    
Accounts payables 36 55
Loans 114
Other current liabilities 120 160
Convertible loans 1,995 2,031
Fair value of convertible component in convertible loans 2,073 1,327
Short term lease liability 27 32
Total Liabilities 4,251 3,719
SHAREHOLDER’S DEFICIT    
Authorized: 500,000,000 shares at June 30, 2023 and December 31, 2022; Issued and Outstanding: 4,215,571 and 4,215,571 shares at June 30, 2023 and December 31, 2022, respectively 4 4
Additional Paid in capital 20,625 19,756
Accumulated deficit (23,786) (22,604)
Shareholders’ deficit (3,157) (2,844)
Non-controlling interests 667 275
Total shareholders’ deficit (2,490) (2,569)
Total liabilities and shareholders’ deficit $ 1,761 $ 1,150
v3.23.2
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Ordinary shares, par value (in Dollars per share) $ 0.0001 $ 0.0001
Ordinary shares, shares authorized 500,000,000 500,000,000
Ordinary shares, shares issued 4,215,571 4,215,571
Ordinary shares, shares outstanding 4,215,571 4,215,571
v3.23.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
Research and development $ 93 $ (211) $ (140) $ (276)
Selling and marketing
General and administrative (146) (209) (305) (301)
Operating loss (53) (420) (445) (577)
Financial income (expenses), net (947) (260) (871) 318
Net loss (1,000) (680) (1,316) (259)
Non-controlling interests (4) (68) (134) (95)
Net loss attributable to equity holders of the Company $ (996) $ (612) $ (1,182) $ (164)
Basic net loss per share (in Dollars per share) $ (0.24) $ (0.15) $ (0.28) $ (0.04)
Weighted average number of Ordinary shares used in computing basic loss per share (in Shares) 4,215,571 4,194,385 4,215,571 4,194,385
v3.23.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Diluted net loss per share $ (0.24) $ (0.15) $ (0.28) $ (0.04)
Weighted average number of ordinary shares used in computing diluted loss per share 4,215,571 4,194,385 4,215,571 4,194,385
v3.23.2
Condensed Consolidated Statements of Changes in Shareholders’ Deficit - USD ($)
$ in Thousands
Ordinary shares
Additional Paid in capital
Accumulated Deficit
Total Shareholders' Deficiency
Non- controlling interests
Total
Balance at Dec. 31, 2021 $ 4 $ 18,595 $ (21,077) $ (2,478) $ 106 $ (2,372)
Balance (in Shares) at Dec. 31, 2021 4,194,385          
Share based compensation to non-controlling parties 117 117 30 147
Share Based Compensation to employees and non-employees 40 40 40
Cancellation of share options in subsidiary (168) (168) (43) (211)
Net income (loss) 448 448 (27) 421
Balance at Mar. 31, 2022 $ 4 18,584 (20,629) (2,041) 66 (1,975)
Balance (in Shares) at Mar. 31, 2022 4,194,385          
Balance at Dec. 31, 2021 $ 4 18,595 (21,077) (2,478) 106 (2,372)
Balance (in Shares) at Dec. 31, 2021 4,194,385          
Net income (loss)           (259)
Balance at Jun. 30, 2022 $ 4 18,720 (21,241) (2,517) 24 (2,493)
Balance (in Shares) at Jun. 30, 2022 4,194,385          
Balance at Mar. 31, 2022 $ 4 18,584 (20,629) (2,041) 66 (1,975)
Balance (in Shares) at Mar. 31, 2022 4,194,385          
Share based compensation to non-controlling parties 101 101 26 127
Share Based Compensation to employees and non-employees 35 35 35
Net income (loss) (612) (612) (68) (680)
Balance at Jun. 30, 2022 $ 4 18,720 (21,241) (2,517) 24 (2,493)
Balance (in Shares) at Jun. 30, 2022 4,194,385          
Balance at Dec. 31, 2022 $ 4 19,756 (22,604) (2,844) 275 (2,569)
Balance (in Shares) at Dec. 31, 2022 4,215,571          
Share based compensation to non-controlling parties 25 25 14 39
Share Based Compensation to employees and non-employees 35 35 35
Transactions with non-controlling parties 767 767 507 1,274
Net income (loss) (186) (186) (130) (316)
Balance at Mar. 31, 2023 $ 4 20,583 (22,790) (2,203) 666 (1,537)
Balance (in Shares) at Mar. 31, 2023 4,215,571          
Balance at Dec. 31, 2022 $ 4 19,756 (22,604) (2,844) 275 (2,569)
Balance (in Shares) at Dec. 31, 2022 4,215,571          
Net income (loss)           (1,316)
Balance at Jun. 30, 2023 $ 4 20,625 (23,786) (3,157) 667 (2,490)
Balance (in Shares) at Jun. 30, 2023 4,215,571          
Balance at Mar. 31, 2023 $ 4 20,583 (22,790) (2,203) 666 (1,537)
Balance (in Shares) at Mar. 31, 2023 4,215,571          
Share based compensation to non-controlling parties 15 15 11 26
Share Based Compensation to employees and non-employees 35 35 35
Cancellation of share options in subsidiary (8) (8) (6) (14)
Net income (loss) (996) (996) (4) (1,000)
Balance at Jun. 30, 2023 $ 4 $ 20,625 $ (23,786) $ (3,157) $ 667 $ (2,490)
Balance (in Shares) at Jun. 30, 2023 4,215,571          
v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (1,316) $ (259)
Adjustments to reconcile loss to net cash used in operating activities:    
Depreciation and amortization 23 27
Share based compensation expenses to employees and non-employees 121 110
Financial expenses related to convertible loans and warrants 91 (1,290)
Change in fair value of convertible component in convertible loans 747 948
Changes in assets and liabilities:    
Decrease in other accounts receivable 36 (30)
Increase in trade payables (19) 34
Decrease in other current liabilities (40) (34)
Net cash used in operating activities (357) (494)
Cash flows from investing activities:    
Decrease (Increase) in short-term deposits (795) 9
Purchase of property and equipment (44) (199)
Net cash used in investing activities (839) (190)
Cash flows from financing activities:    
Proceeds from convertible loans 50
Lease payments (10) (15)
Repayment of convertible loans (121) (75)
Repayment of short term loans (114)
Proceeds from issuance of shares to minority interests in subsidiary 1,273
Net cash provided (used) by financing activities 1,028 (40)
Increase (decrease) in cash and cash equivalents (168) (724)
Cash and cash equivalents at the beginning of the year 810 866
Cash and cash equivalents at the end of the period 642 142
Supplemental disclosures of cash flow information:    
Cash paid for interest 75
Conversion of convertible loans
Purchase of fixed assets by issuance of share capital $ 28
v3.23.2
General
6 Months Ended
Jun. 30, 2023
General [Abstract]  
GENERAL
NOTE 1:- GENERAL

 

  a. SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligent algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 54% of Saffron Tech.

  

The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants and mushrooms. Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.

 

It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. Accounting to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for harmful pesticides and herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.

 

Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the textile industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.

 

  b. The Company has an accumulated deficit in the total amount of $23,786 as of June 30, 2023, the Company has negative operating cash flow in the total amount of $357 for the six months ended June 30, 2023, further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.

 

The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods.

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

 

The consolidated financial statements for the six months ended June 30, 2023, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

v3.23.2
Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Significant Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation:

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”)

 

All intercompany accounts and transactions have been eliminated in consolidation.

 

Unaudited Interim Financial Information

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023 (the “2022 Annual Report”). The results for any interim period are not necessarily indicative of results for any future period.

 

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the three and six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.

 

As of June 30, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report.

 

Fair value of financial instruments

 

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  Level 1 — Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
     
  Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
     
  Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying amounts of cash and cash equivalents, short term deposits, trade receivables, trade payables and short-term loan approximate their fair value due to the short-term maturity of such instruments.

 

The Company elected to measure some of the convertible loans under the fair value option. Under the fair value option the convertible loans will be measured at fair value in each reporting period until they will be converted, with changes in the fair values being recognized in the Company’s consolidated statement of operations as financial income or expense. The proceeds received for the issuance of the convertible loans were allocated at fair value conducted on an arm’s-length basis.

 

The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:

 

   Balance as of June 30, 2023 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $2,073   $2,073 
                     
Total liabilities  $
-
   $
-
   $2,073   $2,073 

 

   Balance as of December 31, 2022 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $1,327   $1,327 
                     
Total liabilities  $
-
   $
-
   $1,327   $1,327 
v3.23.2
Convertible Loans
6 Months Ended
Jun. 30, 2023
Convertible Loans [Abstract]  
CONVERTIBLE LOANS
NOTE 3:- CONVERTIBLE LOANS

 

  a. On February 21, 2019, the Company received a convertible loan from third party (“February 2019 Lender”), with a two-year term, in the principal amount of $550, which bears 10% annual interest rate (“February 2019 Loan”).

 

The Company at its option shall have the right to redeem, in part or in whole, outstanding principal amount and interest under this loan agreement prior to the maturity date. The Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding principal amount being redeemed plus outstanding and accrued interest.

 

The February 2019 Lender shall be entitled to convert at its option any portion of the outstanding and unpaid principal or accrued interest into fully paid and nonassessable of shares of common stock, at the lower of the fixed conversion price then in effect or the market conversion price. The number of shares of common stock issuable upon conversion of any conversion amount shall be determined by dividing (x) such conversion amount by (y) the fixed conversion price of $20.00 or (z) 80% of the lowest the volume-weighted average price of the Company’s shares of common stock during the 30 trading days immediately preceding the conversion date.

 

The Company accounted for the February 2019 Loan in accordance with ASC 470-20, Debt with conversion and other Options. As of December 31, 2022, the BCF was revalued at $326.

 

During the year ended December 31, 2020, a portion of the February 2019 Loan in the amount of $190 and accrued interest of $87 was converted into 1,045,521 Shares.

 

On February 20, 2021, the Company and the February 2019 Lender extended the February 2019 Loan to November 10, 2021.

 

On May 12, 2021, a portion of the February 2019 Loan in the amount of $60 and accrued interest of the February 2019 Loan in the amount of $14 was paid by the Company.

 

On January 26, 2022, the Company paid accrued interest of the February 2019 Loan in the amount of $20, and the February 2019 Loan agreement was extended until December 31, 2022. On December 10, 2022, the February 2019 Loan agreement was extended until June 30, 2023. As of June 30, 2023, the Company has defaulted on the February 2019 Loan. On July 31, the February 2019 Loan agreement was extended until December 30, 2023.

 

Conversion feature

 

In accordance with ASC 815-15-25 the conversion feature was considered an embedded derivative instrument, and is to be recorded at its fair value separately from the convertible notes, within current liabilities in the Company’s balance sheet. The conversion component is then marked to market at each reporting period with the resulting gains or losses shown in the statements of operations.

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $59 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.156 

 

The February 2019 Loan is included in the convertible loans in current liabilities as of June 30, 2023, in the amount of $347, and $332 as of December 31, 2022.

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to February 2019 Loan in the amount of $71, and financial income in the amount of $301 in the six months ended June 30, 2022.

 

  b. On October 15, 2019, the Company received a convertible loan from a third party (“October 2019 Lender”) in the principal amount of $1,100 that bears an annual 10% interest rate (“October 2019 Loan”). The October 2019 Loan has a two-year term. Prior to the maturity date of the October 2019 Loan, the Company, at its option, has the right to redeem, in cash, in part or in whole, the amounts outstanding provided that as of the date of the redemption notice (i) the volume-weighted average price of the Company’s ordinary shares is less than $12.50 and (ii) there is no equity condition failures as defined therein. In the event that the Company wishes to redeem any amount under the convertible loan, the Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding amount being redeemed in addition to outstanding and accrued interest.

 

The October 2019 Lender shall be entitled to convert the principal loan and the outstanding interest (the “Conversion Amount”) into such number of ordinary shares determined by dividing (x) such Conversion Amount by (y) the fixed conversion price of $12.50 or (z) 80% of the lowest the volume-weighted average price of the Company’s ordinary shares during the 10 trading days immediately preceding the conversion date.

 

The Company accounted for the October 2019 Loan in accordance with ASC 470-20, Debt with conversion and other Options. As of December 31, 2022, the BCF was revalued at $732.

 

As of December 31, 2021, the Company has defaulted on the October 2019 Loan and the October 2019 Loan was presented in fair value in financial statements for the year ended December 31, 2021.

 

On January 26, 2022, the Company paid accrued interest of the October 2019 Loan in the amount of $55, and the October 2019 Loan agreement was extended until December 31, 2022.

 

On December 20, 2022, the Company paid accrued interest of the October 2019 Loan in the amount of $100, and the October 2019 Loan agreement was extended until June 30, 2023. As of June 30, 2023, the Company has defaulted on the October 2019 Loan. On July 31, the October 2019 Loan agreement was extended until December 30, 2023.

  

Conversion feature

 

In accordance with ASC 815-15-25 the conversion feature was considered an embedded derivative instrument, and is to be recorded at its fair value separately from the convertible notes, within current liabilities in the Company’s balance sheet. The conversion component is then marked to market at each reporting period with the resulting gains or losses shown in the statements of operations.

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $210 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 

 

The October 2019 Loan is included in the convertible loans in current liabilities as of June 30, 2023, in the amount of $1,259, and $778 as of December 31, 2022.

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to October 2019 Loan in the amount of $678, and financial income in the amount of $1,101 in the six months ended June 30, 2022.

 

  c. On August 7, 2020, the Company received a convertible loan from a third party (“August 2020 Lender”) in the amount of $200 (the “August 2020 Loan”). Per the terms of the Agreement, the August 2020 Loans has a maturity date of August 7, 2022, (“Maturity Date”) and accrues annual interest at a rate of 10%

 

The August 2020 Loan is convertible by the August 2020 Lender into Shares, at their discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).

 

The Company also granted the August 2020 Investor warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $2.00 per share, such exercise price is subject to any future price-based anti-dilution adjustments. Accordance with ASU 2017-11 the warrants were classified in shareholders equity.

 

The fair value of the warrants granted was $35 using the Black-Scholes-Merton option pricing model using the following assumptions:

 

   August
2020
 
Share price  $0.86 
Dividend yield   0%
Risk-free interest rate   0.21%
Expected term (in years)   5 
Volatility   176.96%

 

The Company accounted for the August 2020 Loan in accordance with ASC 470-20, Debt with conversion and other Options. The combined intrinsic value of the BCF for the August 2020 Loan was calculated and valued at $249 as of August 7, 2020, and the Company allocated $249 to the BCF as a liability. As of December 31, 2021, the BCF was revalued at $146 ($339 as of December 31, 2020).

 

As of June 30, 2023, the Company has defaulted on the August 2020 Loan. On July 31, the August 2020 Loan agreement was extended until December 30, 2023.

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $43 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 

 

The August 2020 Loan is included in the convertible loans in short term liabilities as of June 30, 2023 in the amount of $259, and $249 as of December 31, 2022.

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to August 2020 Loan in the amount of $130, and interest and financial expenses in the amount of $44 in the six months ended June 30, 2022.

 

  d. From November 2020 through to December 31, 2020, the Company received $425 from third party investors from the issuance of convertible promissory notes (“2020 Promissory Notes”). The Promissory Notes bear no interest, are convertible into Shares based on a fixed conversion price of $1.00 per share and mature between 6 and 24 months from the issuance date. Pursuant to the 2020 Promissory Notes, one of the investors received warrants to purchase 33,000 Shares at an exercise price of $1.50 through to December 17, 2021. (“2020 Promissory Warrants”)

 

From January 2021 through to February 16, 2021, the Company received an additional $530 from third party investors from the issuance of Promissory Notes (“2021 Promissory Notes). One of the investors received 33,000 warrants (“2021 Promissory Warrants”). The 2021 Promissory Warrants have the same terms as the 2020 Promissory Notes. During December 2021 the 2020 Promissory Warrants and the 2021 Promissory Warrants were extended to December 31, 2022.

 

During the year ended December 31, 2021, Promissory Notes in the amount of $830 have been converted into shares. On December 14, 2022, Promissory Notes in the amount of $100 were repaid to the investors.

 

  e. On July 31, 2020, the Company received a convertible loan from Mr. Shmuel Yannay (a third party at that time, and a director of the Company as of October 28, 2021) in the amount of $100 (“Director Loan”). The loan has a maturity date of July 31, 2022 (“Maturity Date”) and accrues annual interest at a rate of 10%

 

The Director Loan is convertible into Shares, at his discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).

 

The Company also granted the Mr. Yannay warrants to purchase 25,000 shares of common stock of the Company at an exercise price of $2.00 per share, such exercise price is subject to any future price-based anti-dilution adjustments. Accordance with ASU 2017-11 the warrants were classified in shareholders equity.

 

The fair value of the warrants granted was $18 using the Black-Scholes-Merton option pricing model using the following assumptions:

 

   August
2020
 
Share price  $0.86 
Dividend yield   0%
Risk-free interest rate   0.21%
Expected term (in years)   5 
Volatility   176.96%

 

The Company accounted for the director’s loan in accordance with ASC 470-20, Debt with conversion and other Options. The combined intrinsic value of the BCF for the August 2020 Loan was calculated and valued at $129 as of July 31, 2020, and the Company allocated $129 to the BCF as a liability. As of June 30, 2023, the BCF was revalued at $18 ($88 as of December 31, 2022).

 

The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $18 was calculated with the following parameters:

 

   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 

 

During the six months ended June 30, 2023, the Company recorded interest and financial expenses related to Director Loan in the amount of $53, and interest and financial expenses in the amount of $18 in the six months ended June 30, 2022.

v3.23.2
Related Parties
6 Months Ended
Jun. 30, 2023
Related Parties [Abstract]  
RELATED PARTIES
NOTE 4:- RELATED PARTIES

 

The following transactions arose with related parties:

 

   Six months ended June 30, 2023   Amounts
 owing
 
   Directors
Fees
   Consulting
Fees /
Salaries
   Interest   Total   by (to) as of
June 30,
2023
 
Director and CEO  $
       -
   $82   $
-
   $82   $(13)
CFO   
-
    36    
-
    36    (5)
Company controlled by CFO   
-
    26    
-
    26    
-
 
Directors   
-
    42    26    68    (112)
   $
-
   $186   $26   $212   $(130)

 

   Six months ended June 30, 2022   Amounts
 owing
 
   Directors
Fees
   Consulting
Fees /
Salaries
   Interest   Total   by (to) as of
June 30,
2022
 
Director and CEO  $
       -
   $59   $         $59   $
      -
 
CFO   
-
    36         36    (18)
Company controlled by CFO   
-
    26    
-
    26    
-
 
Directors   
-
    
-
    5    5    (115)
   $
-
   $121   $5   $126   $(133)
v3.23.2
Shareholders’ Deficit
6 Months Ended
Jun. 30, 2023
Shareholders' Equity [Abstract]  
SHAREHOLDERS’ DEFICIT
NOTE 5:- SHAREHOLDERS’ DEFICIT

 

  a. As of June 30, 2023 and December 31, 2022, the Company’s share capital is composed as follows:

 

   June 30,
2023
   December 31,
2022
 
   Authorized   Issued and
outstanding
   Issued and
outstanding
   Issued and
outstanding
 
   Number of shares 
Shares of common stock of $0.0001 par value each “Shares”   500,000,000    4,215,571    500,000,000    4,215,571 

 

  b. Warrants

 

A summary of warrant activity during the six months period ended June 30, 2023, and year ended December 31, 2022 is as follows:

 

   Number   Average
exercise
price
 
Warrants outstanding at January 1, 2022   198,750   $5.40 
Granted   
-
    
-
 
Exercised   
-
    
-
 
Forfeited/Cancelled   (13,750)   2.00 
Forfeited/Cancelled   (66,000)   1.50 
Warrants outstanding at December 31, 2022   119,000   $5.88 
Expired   
-
    
-
 
Exercised   
-
    
-
 
Forfeited/Cancelled   
-
    
-
 
Warrants outstanding at June 30, 2023   119,000   $5.88 

 

The following warrants are outstanding as of December 31, 2022:

 

Issuance date  Warrants
outstanding
   Exercise
price per
warrant
   Warrants
outstanding and
exercisable
   Expiry date
October 15, 2019   44,000   $12.50    44,000   October 15, 2024
August 7, 2020   50,000   $2.00    50,000   August 7, 2025
August 11, 2020   25,000   $2.00    25,000   August 11, 2025
    119,000         119,000    

 

The following warrants and are outstanding as of June 30, 2023:

 

Issuance date  Warrants
outstanding
   Exercise
price per
warrant
   Warrants
outstanding and
exercisable
   Expiry date
October 15, 2019   44,000   $12.50    44,000   October 15, 2024
August 7, 2020   50,000   $2.00    50,000   August 7, 2025
August 11, 2020   25,000   $2.00    25,000   August 11, 2025
    119,000         119,000    

 

  c. Share option plans:

 

On April 1, 2019, the Company’s board of directors adopted the Sativus Tech Corp. 2018 Share Options Plan (the “2018 Plan”).

 

Awards granted under the 2018 Plan are subject to vesting schedules and unless determined otherwise by the administrator of the 2018 Plan, generally vest following a period of four years from the applicable vesting commencement date, such that the awards vest in four annual equal instalments and/or generally vest following a period of one year from the applicable vesting commencement date, such that the awards vest in four quarterly equal instalments.

  

(i)A summary of employee share options activity during the six-month period ended June 30, 2023, and for the year ended December 31, 2022, is as follows:

 

   Number   Average
weighted
exercise
price
 
Options outstanding at January 1, 2022   195,000   $0.63 
Granted   45,000    1.00 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Options outstanding at December 31, 2022   240,000   $0.70 
Granted   
-
    
-
 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Options outstanding at June 30, 2023   240,000   $0.70 
           
Options exercisable at June 30, 2023   223,750   $0.72 

 

The following options are outstanding as of June 30, 2022:

 

Issuance date  Options
outstanding
   Exercise
price per
option
   Options
outstanding and
exercisable
   Expiry date
September 1, 2020   15,000   $0.70    13,750   September 1, 2025
October 13, 2020   50,000   $1.00    50,000   October 12, 2023
November 3, 2020   25,000   $1.00    25,000   October 25, 2025
November 3, 2020   25,000   $1.50    25,000   October 25, 2025
December 14, 2021   80,000   $0.01    72,500   December 14, 2026
November 15, 2022   45,000   $1.00    37,500   November 15, 2024
    240,000         223,750    

 

  d. Restricted Share Units:

 

RSUs under the 2018 Plan may be granted upon such terms and conditions, no monetary payment (other than payments made for applicable taxes) shall be required as a condition of receiving the Company’s shares pursuant to a grant of RSUs, and unless determined otherwise by the Company, the aggregate nominal value of such RSUs shall not be paid and the Company shall capitalize applicable profits or take any other action to ensure that it meets any requirement of applicable laws regarding issuance of shares for consideration that is lower than the nominal value of such shares. If, however, the Company’s board of directors determines that the nominal value of the shares shall not be waived and shall be paid by the grantees, then it shall determine procedures for payment of such nominal value by the grantees or for collection of such amount from the grantees by the Company.

 

Shares issued pursuant to any RSUs units may (but need not) be made subject to exercise conditions, as shall be established by the Company and set forth in the applicable notice of grant evidencing such award. During any restriction period in which shares acquired pursuant to an award of RSUs remain subject to exercise conditions, such shares may not be sold, exchanged, transferred, pledged, assigned or otherwise disposed of unless otherwise provided in the 2018 Plan. Upon request by the Company, each grantee shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares hereunder and the Company may place appropriate legends evidencing any such transfer restrictions on the relevant share certificates.

 

A summary of RSU activity during the six months ended June 30, 2023, and the year ended December 31, 2022 is as follows:

 

    Number  
RSU outstanding at January 1, 2022     196,000  
Granted     370,000  
Exercised     -  
Forfeited     (30,000 )
RSU outstanding at December 31, 2022     536,000  
Granted     -  
Exercised     -  
Forfeited     (5,000
RSU’s outstanding at June 30, 2022     531,000  
v3.23.2
Financial Income (Expenses)
6 Months Ended
Jun. 30, 2023
Financial Income (Expenses) [Abstract]  
FINANCIAL INCOME (EXPENSES)
NOTE 6:- FINANCIAL INCOME (EXPENSES)

 

   Three months ended   Six months ended 
   June 30,
2023
   June 30,
2022
   June 30,
2023
   June 30,
2022
 
                 
Financial income (expenses) related to interest and revaluation of convertible component in convertible loans  $(911  $(250)  $(832  $346 
                     
Financial expenses related to warrants   
-
    
-
    
-
    
-
 
                     
Foreign currency transactions and other   (36)   (10)   (39)   (28)
                     
    (947   (260)   (871   318 
v3.23.2
Liens, Commitments
6 Months Ended
Jun. 30, 2023
Liens, Commitments [Abstract]  
LIENS, COMMITMENTS
NOTE 7:- LIENS, COMMITMENTS

 

Saffron leases its facility on a lease that expires on September 11, 2024. Lease payments are approximately $2 per month ($23 annually).  

 

Saffron Tech is committed to pay royalties to the IIA on the proceeds from sales of products resulting from research and development projects in which the IIA participates by way of grants. In the first 3 years of sales the Company shall pay 3% of the sales of the product which was developed under IIA research and development projects. In the fourth, fifth and sixth years of sales, the Company shall pay 4% of such sales and from the seventh year onwards the Company shall pay 5% of up to 100% of the amount of grants received plus interest at LIBOR. Saffron Tech was entitled to the grants only upon incurring research and development expenditures. There were no future performance obligations related to the grants received from the IIA. As of June 30, 2023, the contingent liabilities with respect to grants received from the IIA, subject to repayment under these royalty agreements on future sales is $Nil. As of June 30, 2023, Saffron Tech received a total of $395 from the IIA

v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
  NOTE 8:- SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report. 

v3.23.2
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2023
Significant Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation:

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”)

All intercompany accounts and transactions have been eliminated in consolidation.

Unaudited Interim Financial Information

Unaudited Interim Financial Information

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023 (the “2022 Annual Report”). The results for any interim period are not necessarily indicative of results for any future period.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the three and six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.

As of June 30, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report.

 

Fair value of financial instruments

Fair value of financial instruments

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

  Level 1 — Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
     
  Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
     
  Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The carrying amounts of cash and cash equivalents, short term deposits, trade receivables, trade payables and short-term loan approximate their fair value due to the short-term maturity of such instruments.

The Company elected to measure some of the convertible loans under the fair value option. Under the fair value option the convertible loans will be measured at fair value in each reporting period until they will be converted, with changes in the fair values being recognized in the Company’s consolidated statement of operations as financial income or expense. The proceeds received for the issuance of the convertible loans were allocated at fair value conducted on an arm’s-length basis.

The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:

   Balance as of June 30, 2023 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $2,073   $2,073 
                     
Total liabilities  $
-
   $
-
   $2,073   $2,073 
   Balance as of December 31, 2022 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $1,327   $1,327 
                     
Total liabilities  $
-
   $
-
   $1,327   $1,327 
v3.23.2
Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Significant Accounting Policies [Abstract]  
Schedule of Financial Assets and Liabilities That are Measured at Fair Value The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:
   Balance as of June 30, 2023 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $2,073   $2,073 
                     
Total liabilities  $
-
   $
-
   $2,073   $2,073 
   Balance as of December 31, 2022 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs  $
-
   $
-
   $1,327   $1,327 
                     
Total liabilities  $
-
   $
-
   $1,327   $1,327 
v3.23.2
Convertible Loans (Tables)
6 Months Ended
Jun. 30, 2023
Convertible Loans [Abstract]  
Schedule of Fair Value of the Warrants Granted The fair value of the conversion feature (hereafter “Convertible Component”) in the amount of $59 was calculated with the following parameters:
   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.156 
   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 
   August
2020
 
Share price  $0.86 
Dividend yield   0%
Risk-free interest rate   0.21%
Expected term (in years)   5 
Volatility   176.96%
   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 
   August
2020
 
Share price  $0.86 
Dividend yield   0%
Risk-free interest rate   0.21%
Expected term (in years)   5 
Volatility   176.96%
   June 30,
2023
 
Share price  $0.327 
80% of the lowest the volume-weighted average price  $0.160 
v3.23.2
Related Parties (Tables)
6 Months Ended
Jun. 30, 2023
Related Parties [Abstract]  
Schedule of Related Party Transactions The following transactions arose with related parties:
   Six months ended June 30, 2023   Amounts
 owing
 
   Directors
Fees
   Consulting
Fees /
Salaries
   Interest   Total   by (to) as of
June 30,
2023
 
Director and CEO  $
       -
   $82   $
-
   $82   $(13)
CFO   
-
    36    
-
    36    (5)
Company controlled by CFO   
-
    26    
-
    26    
-
 
Directors   
-
    42    26    68    (112)
   $
-
   $186   $26   $212   $(130)
   Six months ended June 30, 2022   Amounts
 owing
 
   Directors
Fees
   Consulting
Fees /
Salaries
   Interest   Total   by (to) as of
June 30,
2022
 
Director and CEO  $
       -
   $59   $         $59   $
      -
 
CFO   
-
    36         36    (18)
Company controlled by CFO   
-
    26    
-
    26    
-
 
Directors   
-
    
-
    5    5    (115)
   $
-
   $121   $5   $126   $(133)
v3.23.2
Shareholders’ Deficit (Tables)
6 Months Ended
Jun. 30, 2023
Shareholders' Equity [Abstract]  
Schedule of Company’s Share Capital As of June 30, 2023 and December 31, 2022, the Company’s share capital is composed as follows:
   June 30,
2023
   December 31,
2022
 
   Authorized   Issued and
outstanding
   Issued and
outstanding
   Issued and
outstanding
 
   Number of shares 
Shares of common stock of $0.0001 par value each “Shares”   500,000,000    4,215,571    500,000,000    4,215,571 
Schedule of Warrant Activity A summary of warrant activity during the six months period ended June 30, 2023, and year ended December 31, 2022 is as follows:
   Number   Average
exercise
price
 
Warrants outstanding at January 1, 2022   198,750   $5.40 
Granted   
-
    
-
 
Exercised   
-
    
-
 
Forfeited/Cancelled   (13,750)   2.00 
Forfeited/Cancelled   (66,000)   1.50 
Warrants outstanding at December 31, 2022   119,000   $5.88 
Expired   
-
    
-
 
Exercised   
-
    
-
 
Forfeited/Cancelled   
-
    
-
 
Warrants outstanding at June 30, 2023   119,000   $5.88 

 

Schedule of Warrants are Outstanding The following warrants are outstanding as of December 31, 2022:
Issuance date  Warrants
outstanding
   Exercise
price per
warrant
   Warrants
outstanding and
exercisable
   Expiry date
October 15, 2019   44,000   $12.50    44,000   October 15, 2024
August 7, 2020   50,000   $2.00    50,000   August 7, 2025
August 11, 2020   25,000   $2.00    25,000   August 11, 2025
    119,000         119,000    
Issuance date  Warrants
outstanding
   Exercise
price per
warrant
   Warrants
outstanding and
exercisable
   Expiry date
October 15, 2019   44,000   $12.50    44,000   October 15, 2024
August 7, 2020   50,000   $2.00    50,000   August 7, 2025
August 11, 2020   25,000   $2.00    25,000   August 11, 2025
    119,000         119,000    
Schedule of Employee Share Options Activity A summary of employee share options activity during the six-month period ended June 30, 2023, and for the year ended December 31, 2022, is as follows:
   Number   Average
weighted
exercise
price
 
Options outstanding at January 1, 2022   195,000   $0.63 
Granted   45,000    1.00 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Options outstanding at December 31, 2022   240,000   $0.70 
Granted   
-
    
-
 
Exercised   
-
    
-
 
Forfeited   
-
    
-
 
Options outstanding at June 30, 2023   240,000   $0.70 
           
Options exercisable at June 30, 2023   223,750   $0.72 

 

Schedule of Option Outstanding Activity The following options are outstanding as of June 30, 2022:
Issuance date  Options
outstanding
   Exercise
price per
option
   Options
outstanding and
exercisable
   Expiry date
September 1, 2020   15,000   $0.70    13,750   September 1, 2025
October 13, 2020   50,000   $1.00    50,000   October 12, 2023
November 3, 2020   25,000   $1.00    25,000   October 25, 2025
November 3, 2020   25,000   $1.50    25,000   October 25, 2025
December 14, 2021   80,000   $0.01    72,500   December 14, 2026
November 15, 2022   45,000   $1.00    37,500   November 15, 2024
    240,000         223,750    
Schedule of RSU Activity A summary of RSU activity during the six months ended June 30, 2023, and the year ended December 31, 2022 is as follows:
    Number  
RSU outstanding at January 1, 2022     196,000  
Granted     370,000  
Exercised     -  
Forfeited     (30,000 )
RSU outstanding at December 31, 2022     536,000  
Granted     -  
Exercised     -  
Forfeited     (5,000
RSU’s outstanding at June 30, 2022     531,000  
v3.23.2
Financial Income (Expenses) (Tables)
6 Months Ended
Jun. 30, 2023
Financial Income (Expenses) [Abstract]  
Schedule of Financial Income (Expenses) FINANCIAL INCOME (EXPENSES)
   Three months ended   Six months ended 
   June 30,
2023
   June 30,
2022
   June 30,
2023
   June 30,
2022
 
                 
Financial income (expenses) related to interest and revaluation of convertible component in convertible loans  $(911  $(250)  $(832  $346 
                     
Financial expenses related to warrants   
-
    
-
    
-
    
-
 
                     
Foreign currency transactions and other   (36)   (10)   (39)   (28)
                     
    (947   (260)   (871   318 
v3.23.2
General (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Nov. 05, 2020
General (Details) [Line Items]        
Accumulated deficit $ (23,786)   $ (22,604)  
Operating cash flow $ (357) $ (494)    
Saffron Tech [Member]        
General (Details) [Line Items]        
Ownership percentage       54.00%
v3.23.2
Significant Accounting Policies (Details) - Schedule of Financial Assets and Liabilities That are Measured at Fair Value - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Significant Accounting Policies (Details) - Schedule of Financial Assets and Liabilities That are Measured at Fair Value [Line Items]    
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs $ 2,073 $ 1,327
Total liabilities 2,073 1,327
Level 1 [Member]    
Significant Accounting Policies (Details) - Schedule of Financial Assets and Liabilities That are Measured at Fair Value [Line Items]    
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs
Total liabilities
Level 2 [Member]    
Significant Accounting Policies (Details) - Schedule of Financial Assets and Liabilities That are Measured at Fair Value [Line Items]    
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs
Total liabilities
Level 3 [Member]    
Significant Accounting Policies (Details) - Schedule of Financial Assets and Liabilities That are Measured at Fair Value [Line Items]    
Fair Value of convertible component in convertible loan, net of discounts and debt issue costs 2,073 1,327
Total liabilities $ 2,073 $ 1,327
v3.23.2
Convertible Loans (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended 12 Months Ended
Dec. 20, 2022
Dec. 14, 2022
Jan. 26, 2022
Dec. 17, 2021
May 12, 2021
Aug. 07, 2020
Jul. 31, 2020
Oct. 15, 2019
Feb. 21, 2019
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2022
Feb. 16, 2021
Convertible Loans (Details) [Line Items]                              
Principal loan amount                 $ 550            
Interest rate                 10.00%            
Revalued amount                     $ 326        
Accrued interest         $ 60                    
Loan amount     $ 20   $ 14                    
Fair value of conversion                   $ 18          
Revalued values of BCF                   18 $ 88        
Maturity date             Jul. 31, 2022                
Warrants granted                   $ 18          
Convertible             $ 100                
Annual interest rate             10.00%                
Weighted average price (in Dollars per share)                   $ 0.7 $ 0.7 $ 0.63      
Intrinsic value                   $ 129          
Interest and financial income                   $ 53       $ 18  
VWAP [Member]                              
Convertible Loans (Details) [Line Items]                              
Lowest the volume-weighted average price                   80.00%          
Minimum [Member]                              
Convertible Loans (Details) [Line Items]                              
Issuance date                   6 years          
Maximum [Member]                              
Convertible Loans (Details) [Line Items]                              
Issuance date                   24 years          
Fixed Conversion Price [Member]                              
Convertible Loans (Details) [Line Items]                              
Conversion price (in Dollars per share)                   $ 1.02          
BCF [Member]                              
Convertible Loans (Details) [Line Items]                              
Intrinsic value             $ 129                
February 2019 Lender [Member]                              
Convertible Loans (Details) [Line Items]                              
Percentage of redemption premium                 20.00%            
Conversion price (in Dollars per share)                 $ 20            
Lowest the volume-weighted average price                 80.00%            
February 2019 Loan [Member]                              
Convertible Loans (Details) [Line Items]                              
Loan amount                         $ 190    
Accrued interest                         $ 87    
Debt converted shares (in Shares)                         1,045,521    
Fair value of conversion                   $ 59          
Debt amount                   347 $ 332        
Debt interest and financial expenses                   $ 71       301  
Convertible Loan [Member]                              
Convertible Loans (Details) [Line Items]                              
Convertible loan, description               the Company received a convertible loan from a third party (“October 2019 Lender”) in the principal amount of $1,100 that bears an annual 10% interest rate (“October 2019 Loan”). The October 2019 Loan has a two-year term. Prior to the maturity date of the October 2019 Loan, the Company, at its option, has the right to redeem, in cash, in part or in whole, the amounts outstanding provided that as of the date of the redemption notice (i) the volume-weighted average price of the Company’s ordinary shares is less than $12.50 and (ii) there is no equity condition failures as defined therein. In the event that the Company wishes to redeem any amount under the convertible loan, the Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding amount being redeemed in addition to outstanding and accrued interest.              
October 2019 Lender [Member]                              
Convertible Loans (Details) [Line Items]                              
Conversion price (in Dollars per share)                   $ 12.5          
Lowest the volume-weighted average price                   80.00%          
October 2019 Loan [Member]                              
Convertible Loans (Details) [Line Items]                              
Loan amount $ 100   $ 55                        
Fair value of conversion                   $ 210          
Debt amount                   1,259 778        
Debt interest and financial expenses                   678       1,101  
Revalued values of BCF                     732        
August 2020 Loan [Member]                              
Convertible Loans (Details) [Line Items]                              
Fair value of conversion                   43          
Debt interest and financial expenses                           $ 44  
Revalued values of BCF                       $ 146 $ 339    
Fair value convertible loan           $ 200                  
Maturity date           Aug. 07, 2022                  
Interest rate           10.00%                  
Debentures description           The August 2020 Loan is convertible by the August 2020 Lender into Shares, at their discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).                  
Investor warrants shares (in Shares)           50,000                  
Exercise price (in Dollars per share)           $ 2                  
Warrants granted                   35          
Warrants value                   249          
Warrant allocated amount                   249          
Convertible loans in short term liabilities                   259 $ 249        
August 2020 Lenders [Member]                              
Convertible Loans (Details) [Line Items]                              
Debt interest and financial expenses                   $ 130          
2020 Promissory Notes [Member]                              
Convertible Loans (Details) [Line Items]                              
Conversion price (in Dollars per share)                         $ 1    
Exercise price (in Dollars per share)       $ 1.5                      
Debt amount                         $ 425    
Purchase warrants (in Shares)       33,000                      
2021 Promissory Notes [Member]                              
Convertible Loans (Details) [Line Items]                              
Debt amount                             $ 530
Warrants issued (in Shares)                             33,000
Promissory Notes [Member]                              
Convertible Loans (Details) [Line Items]                              
Promissory amount                       $ 830      
Repaid to investors   $ 100                          
Mr. Yannay [Member]                              
Convertible Loans (Details) [Line Items]                              
Debt converted shares (in Shares)                   25,000          
Weighted average price (in Dollars per share)                   $ 2          
v3.23.2
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted - $ / shares
1 Months Ended 6 Months Ended
Aug. 20, 2020
Jun. 30, 2023
Monte Carlo Simulation Model [Member] | Minimum [Member]    
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted [Line Items]    
Share price   $ 0.327
80% of the lowest the volume-weighted average price   0.156
Monte Carlo Simulation Model [Member] | Maximum [Member]    
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted [Line Items]    
Share price   0.327
80% of the lowest the volume-weighted average price   0.16
Black-Scholes-Merton Option [Member]    
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted [Line Items]    
Share price $ 0.86 0.327
Dividend yield 0.00%  
Risk-free interest rate 0.21%  
Expected term (in years) 5 years  
Volatility 176.96%  
80% of the lowest the volume-weighted average price   0.16
Monte Carlo Option [Member]    
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted [Line Items]    
Share price $ 0.86 0.327
Dividend yield 0.00%  
Risk-free interest rate 0.21%  
Expected term (in years) 5 years  
Volatility 176.96%  
80% of the lowest the volume-weighted average price   $ 0.16
v3.23.2
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted (Parentheticals)
Jun. 30, 2023
$ / shares
Monte Carlo Simulation Model [Member] | Minimum [Member]  
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted (Parentheticals) [Line Items]  
Lowest the volume-weighted average price $ 80
Monte Carlo Simulation Model [Member] | Maximum [Member]  
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted (Parentheticals) [Line Items]  
Lowest the volume-weighted average price 80
Black-Scholes-Merton Option [Member]  
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted (Parentheticals) [Line Items]  
Lowest the volume-weighted average price 80
Monte Carlo Option [Member]  
Convertible Loans (Details) - Schedule of Fair Value of the Warrants Granted (Parentheticals) [Line Items]  
Lowest the volume-weighted average price $ 80
v3.23.2
Related Parties (Details) - Schedule of Related Party Transactions - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Related Party Transaction [Line Items]    
Directors Fees
Consulting Fees / Salaries 186 121
Share based awards 26 5
Total 212 126
Amounts owing (130) (133)
Director and CEO [Member]    
Related Party Transaction [Line Items]    
Directors Fees
Consulting Fees / Salaries 82 59
Share based awards  
Total 82 59
Amounts owing (13)
CFO [Member]    
Related Party Transaction [Line Items]    
Directors Fees
Consulting Fees / Salaries 36 36
Share based awards  
Total 36 36
Amounts owing (5) (18)
Company controlled by CFO [Member]    
Related Party Transaction [Line Items]    
Directors Fees
Consulting Fees / Salaries 26 26
Share based awards
Total 26 26
Amounts owing
Directors [Member]    
Related Party Transaction [Line Items]    
Directors Fees
Consulting Fees / Salaries 42
Share based awards 26 5
Total 68 5
Amounts owing $ (112) $ (115)
v3.23.2
Shareholders’ Deficit (Details)
6 Months Ended
Jun. 30, 2023
2018 Plan [Member]  
Shareholders’ Deficit (Details) [Line Items]  
Awards granted, descriptions Awards granted under the 2018 Plan are subject to vesting schedules and unless determined otherwise by the administrator of the 2018 Plan, generally vest following a period of four years from the applicable vesting commencement date, such that the awards vest in four annual equal instalments and/or generally vest following a period of one year from the applicable vesting commencement date, such that the awards vest in four quarterly equal instalments.
v3.23.2
Shareholders’ Deficit (Details) - Schedule of Company’s Share Capital - Common Stock [Member] - shares
Jun. 30, 2023
Dec. 31, 2022
Schedule of Company's Share Capital [Abstract]    
Common stock shares, Authorized 500,000,000 500,000,000
Common stock shares, Issued and outstanding 4,215,571 4,215,571
v3.23.2
Shareholders’ Deficit (Details) - Schedule of Warrant Activity - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Schedule of Warrant Activity [Abstract]    
Number, Warrant outstanding at beginning 119,000 198,750
Average exercise price, beginning $ 5.88 $ 5.4
Number, Warrant outstanding at ending 119,000 119,000
Average exercise price, Warrant outstanding at ending $ 5.88 $ 5.88
Number, Granted  
Average exercise price, Granted  
Number, Expired  
Average exercise price, Expired  
Number, Exercised
Average exercise price, Exercised
Number, Forfeited/Cancelled (13,750)
Average exercise price, Forfeited/Cancelled $ 2
Number, Forfeited/Cancelled   (66,000)
Average exercise price, Forfeited/Cancelled   $ 1.5
v3.23.2
Shareholders’ Deficit (Details) - Schedule of Warrants are Outstanding - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Shareholders’ Deficit (Details) - Schedule of Warrants are Outstanding [Line Items]    
Warrants outstanding 119,000 119,000
Warrants outstanding and exercisable 119,000 119,000
October 15, 2019 [Member]    
Shareholders’ Deficit (Details) - Schedule of Warrants are Outstanding [Line Items]    
Warrants outstanding 44,000 44,000
Exercise price per warrant (in Dollars per share) $ 12.5 $ 12.5
Warrants outstanding and exercisable 44,000 44,000
Expiry date Oct. 15, 2024 Oct. 15, 2024
August 7, 2020 [Member]    
Shareholders’ Deficit (Details) - Schedule of Warrants are Outstanding [Line Items]    
Warrants outstanding 50,000 50,000
Exercise price per warrant (in Dollars per share) $ 2 $ 2
Warrants outstanding and exercisable 50,000 50,000
Expiry date Aug. 07, 2025 Aug. 07, 2025
August 11, 2020 [Member]    
Shareholders’ Deficit (Details) - Schedule of Warrants are Outstanding [Line Items]    
Warrants outstanding 25,000 25,000
Exercise price per warrant (in Dollars per share) $ 2 $ 2
Warrants outstanding and exercisable 25,000 25,000
Expiry date Aug. 11, 2025 Aug. 11, 2025
v3.23.2
Shareholders’ Deficit (Details) - Schedule of Employee Share Options Activity - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Schedule of Employee Share Options Activity [Abstract]    
Number, Options outstanding Beginning balance 240,000 195,000
Average weighted exercise price, Options outstanding Beginnng balance $ 0.7 $ 0.63
Number, Options outstanding Ending balance 240,000 240,000
Average weighted exercise price, Options outstanding Ending balance $ 0.7 $ 0.7
Number, Options exercisable outstanding Ending balance 223,750  
Average weighted exercise price, Options exercisable outstanding Ending balance $ 0.72  
Number, Granted 45,000
Average weighted exercise price, Granted $ 1
Number, Exercised
Average weighted exercise price, Exercised
Number, Forfeited
Average weighted exercise price, Forfeited
v3.23.2
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity
6 Months Ended
Jun. 30, 2022
shares
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 240,000
Options outstanding and exercisable 223,750
September 1, 2020 [Member]  
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 15,000
Exercise price per option 0.7
Options outstanding and exercisable 13,750
Expiry date September 1, 2025
October 13, 2020 [Member]  
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 50,000
Exercise price per option 1
Options outstanding and exercisable 50,000
Expiry date October 12, 2023
November 3, 2020 [Member]  
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 25,000
Exercise price per option 1
Options outstanding and exercisable 25,000
Expiry date October 25, 2025
November 3, 2020 One [Member]  
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 25,000
Exercise price per option 1.5
Options outstanding and exercisable 25,000
Expiry date October 25, 2025
December 14, 2021 [Member]  
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 80,000
Exercise price per option 0.01
Options outstanding and exercisable 72,500
Expiry date December 14, 2026
November 15, 2022 [Member]  
Shareholders’ Deficit (Details) - Schedule of Option Outstanding Activity [Line Items]  
Options outstanding 45,000
Exercise price per option 1
Options outstanding and exercisable 37,500
Expiry date November 15, 2024
v3.23.2
Shareholders’ Deficit (Details) - Schedule of RSU Activity - shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Schedule of RSU Activity [Abstract]    
Number, RSU's outstanding at the beginning 536,000 196,000
Number, RSU's outstanding at the end 531,000 536,000
Number, Granted 370,000
Number, Exercised
Number, Forfeited (5,000) (30,000)
v3.23.2
Financial Income (Expenses) (Details) - Schedule of Financial Income (Expenses) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Schedule of Financial Expenses [Abstract]        
Financial income (expenses) related to interest and revaluation of convertible component in convertible loans $ (911) $ (250) $ (832) $ 346
Financial expenses related to warrants
Foreign currency transactions and other (36) (10) (39) (28)
Total $ (947) $ (260) $ (871) $ 318
v3.23.2
Liens, Commitments (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Liens, Commitments [Abstract]  
Lease expires date Sep. 11, 2024
Lease payments per month $ 2
Lease payment annually $ 23
Percentage of sales, description In the first 3 years of sales the Company shall pay 3% of the sales of the product which was developed under IIA research and development projects. In the fourth, fifth and sixth years of sales, the Company shall pay 4% of such sales and from the seventh year onwards the Company shall pay 5% of up to 100% of the amount of grants received plus interest at LIBOR.
Future sales
Tech received $ 395

Sativus Tech (PK) (USOTC:SATT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Sativus Tech (PK) Charts.
Sativus Tech (PK) (USOTC:SATT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Sativus Tech (PK) Charts.